InMed appoints Netta Jagpal as CFO and Corporate Secretary effective Feb 20, 2024

InMed Pharmaceuticals Inc.

Netta Jagpal appointed CFO and Corporate Secretary effective Feb 20, 2024; replaces Jonathan Tegge as Interim CFO.
Annual base salary of CAD$325,000; eligible for annual discretionary bonus target of 40% of base salary.
Initial grant of 50,000 stock options subject to corporate approvals under the company's stock option plan.
Ms. Jagpal brings over 20 years of biotech finance experience from D-Wave Systems, Zymeworks, Angiotech, and Ernst & Young.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jonathan Tegge

Interim Chief Financial Officer

INM · InMed Pharmaceuticals Inc.

Effective: 2024-02-20
Successor: Netta Jagpal
Filed: February 9, 2024, 6:59 PM ET

Mr. Tegge will cease, pursuant to the terms of his resignation delivered to the Company on February 8, 2024, to serve as the Company’s Interim Chief Financial Officer

Appointed

Netta Jagpal

Chief Financial Officer and Corporate Secretary

INM · InMed Pharmaceuticals Inc.

Effective: 2024-02-20
Filed: February 9, 2024, 6:59 PM ET

appointed Ms. N. Netta “Neeta” Jagpal (“ Ms. Jagpal ”) ( aged 51 ) to serve, effective as of February 20, 2024 (the “ Effective Date ”), as Chief Financial Officer and Corporate Secretary of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jonathan Tegge resigned as Interim Chief Financial Officer at InMed Pharmaceuticals Inc..

Action: resigned
Role: Interim Chief Financial Officer

Exact text from the filing

Mr. Tegge will cease, pursuant to the terms of his resignation delivered to the Company on February 8, 2024, to serve as the Company’s Interim Chief Financial Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Netta Jagpal was appointed as Chief Financial Officer and Corporate Secretary at InMed Pharmaceuticals Inc..

Action: appointed
Role: Chief Financial Officer and Corporate Secretary

Exact text from the filing

appointed Ms. N. Netta “Neeta” Jagpal (“ Ms. Jagpal ”) ( aged 51 ) to serve, effective as of February 20, 2024 (the “ Effective Date ”), as Chief Financial Officer and Corporate Secretary of the Company.

View on SEC.gov

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-011954

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.